Your browser doesn't support javascript.
loading
Improving Early Recognition of Treatment-Responsive Causes of Rapidly Progressive Dementia: The STAM3 P Score.
Satyadev, Nihal; Tipton, Philip W; Martens, Yuka; Dunham, S Richard; Geschwind, Michael D; Morris, John C; Brier, Matthew R; Graff-Radford, Neill R; Day, Gregory S.
Afiliação
  • Satyadev N; Department of Neurology, Mayo Clinic Florida, Jacksonville, Florida, USA.
  • Tipton PW; Georgia Institute of Technology, Atlanta, Georgia, USA.
  • Martens Y; Department of Neurology, Mayo Clinic Florida, Jacksonville, Florida, USA.
  • Dunham SR; Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida, USA.
  • Geschwind MD; Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA.
  • Morris JC; University of California San Francisco, Department of Neurology, Memory and Aging Center, San Francisco, California, USA.
  • Brier MR; Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA.
  • Graff-Radford NR; Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA.
  • Day GS; Department of Neurology, Mayo Clinic Florida, Jacksonville, Florida, USA.
Ann Neurol ; 95(2): 237-248, 2024 Feb.
Article em En | MEDLINE | ID: mdl-37782554
ABSTRACT

OBJECTIVE:

To improve the timely recognition of patients with treatment-responsive causes of rapidly progressive dementia (RPD).

METHODS:

A total of 226 adult patients with suspected RPD were enrolled in a prospective observational study and followed for up to 2 years. Diseases associated with RPD were characterized as potentially treatment-responsive or non-responsive, referencing clinical literature. Disease progression was measured using Clinical Dementia Rating® Sum-of-Box scores. Clinical and paraclinical features associated with treatment responsiveness were assessed using multivariable logistic regression. Findings informed the development of a clinical criterion optimized to recognize patients with potentially treatment-responsive causes of RPD early in the diagnostic evaluation.

RESULTS:

A total of 155 patients met defined RPD criteria, of whom 86 patients (55.5%) had potentially treatment-responsive causes. The median (range) age-at-symptom onset in patients with RPD was 68.9 years (range 22.0-90.7 years), with a similar number of men and women. Seizures, tumor (disease-associated), magnetic resonance imaging suggestive of autoimmune encephalitis, mania, movement abnormalities, and pleocytosis (≥10 cells/mm3 ) in cerebrospinal fluid at presentation were independently associated with treatment-responsive causes of RPD after controlling for age and sex. Those features at presentation, as well as age-at-symptom onset <50 years (ie, STAM3 P), captured 82 of 86 (95.3%) cases of treatment-responsive RPD. The presence of ≥3 STAM3 P features had a positive predictive value of 100%.

INTERPRETATION:

Selected features at presentation reliably identified patients with potentially treatment-responsive causes of RPD. Adaptation of the STAM3 P screening score in clinical practice may minimize diagnostic delays and missed opportunities for treatment in patients with suspected RPD. ANN NEUROL 2024;95237-248.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Demência / Encefalite Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Neurol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Demência / Encefalite Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Neurol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos